Rein Therapeutics
RNTX
28 hedge funds and large institutions have $3.58M invested in Rein Therapeutics in 2020 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 9 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
0.07% less ownership
Funds ownership: 0.52% → 0.45% (-0.07%)
3% less funds holding
Funds holding: 29 → 28 (-1)
11% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 9
23% less capital invested
Capital invested by funds: $4.65M → $3.58M (-$1.07M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$310K |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$227K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$50.7K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$47.9K |
| 5 |
MS
Maven Securities
St Helier,
Jersey
|
+$41.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBVA
Banco Bilbao Vizcaya Argentaria
Madrid,
Spain
|
-$1.01M |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$531K |
| 3 |
Renaissance Technologies
New York
|
-$211K |
| 4 |
TCM
Traynor Capital Management
Malvern,
Pennsylvania
|
-$118K |
| 5 |
Squarepoint
New York
|
-$112K |
RNTX Hedge Fund Activity: Q3 2020 in Review
28 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Rein Therapeutics (RNTX) for Q3 2020, worth a combined $3.58M — down 23% from $4.65M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of RNTX and 8 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 8 added.
The largest buyer was Endurant Capital Management, opening a new position worth an estimated $310K. The largest seller was Banco Bilbao Vizcaya Argentaria, exiting entirely with an estimated $1.01M sold.
- 28 institutional investors held Rein Therapeutics (RNTX) as of Q3 2020, down from 29 in Q2 2020.
- Funds reported $3.58M of Rein Therapeutics stock for Q3 2020, down 23% quarter-over-quarter.
- 8 funds opened new Rein Therapeutics positions in Q3 2020 and 9 closed out, a net change of -1 holder.
- The largest Rein Therapeutics buyer in Q3 2020 was Endurant Capital Management, an estimated $310K added.
- The largest Rein Therapeutics seller in Q3 2020 was Banco Bilbao Vizcaya Argentaria, an estimated $1.01M sold.
Based on aggregated 13F filings for Q3 2020.